


Scott Shepherd
165 posts

@stcshepherd
Honorary Medical Oncology Consultant @royalmarsdennhs | NIHR Clinical Lecturer @TurajlicLab @TheCrick @rmresearch_ @ICR











1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author @BraunMDPhD @YaleCancer and #PatrickOtt #DerinKeskin #CatherineWu @DanaFarber nature.com/articles/s4158… @DanaFarber_GU @OncoAlert @DFCI_NeoVax

Today is a very special day for patients with RCC : CHMP as approved BELZUTIFAN both for VHL disease associated RCC and for advanced renal cell carcinomas (following CPI and 2 VEGFR TKIs) Data presented at @myESMO and published in @NEJM



We are thrilled to welcome Dr. @dhruva_biswas to our team as a research fellow from the UK! Dhruva will focus on advancing machine learning applications to identify high-risk patients. Read his full bio at cards-lab.org/updates/welcom…

We just published a review of lessons farmers have learned for how to control pesticide resistance from evolving, and how to apply those to oncology to prevent cancers from evolving therapeutic resistance: bit.ly/48OfFdX

ecDNA are rogue genetic material that amplify genes, contribute to treatment resistance and drive genomic heterogeneity. We report on the Origins and impact of extrachromosomal DNA today in @Nature nature.com/articles/s4158…


Our Chair, Dr Michael Jewett, was pleased to participate in the International Neoadjuvant Renal Cancer Consortium Meeting in Amsterdam on October 24-25. The IKCC was pleased to support expert clinicians and scientists committed to addressing an unmet need in the treatment of kidney cancer patients. It was a great opportunity to continue discussions from a meeting in January with experts representing urologists, medical oncologists, radiologists, pathologists and clinician scientists, as well representatives from patient organisations. #KidneyCancer








